BC Innovations | Nov 15, 2018
Translation in Brief

The bystander effect of Treg depletion

Limiting bystander effects of immunosuppressive Treg-targeting therapies may be crucial for their antitumor efficacy, according to data released last week at the Society for Immunotherapy of Cancer meeting. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) presented...
BC Innovations | Aug 10, 2017
Emerging Company Profile

Flexing against suppression

FLX Bio Inc. is creating small molecules to dim immunosuppressive actors in the tumor microenvironment without the baggage of the antibodies dominating the immuno-oncology space. Armed with $79 million in series A and B funds,...
BC Innovations | Jul 31, 2017
Distillery Techniques


TECHNOLOGY: Tool compounds A quinolin-2-one-based inhibitor of BRPF1 , BRPF3 and BRD1 could be useful for probing the roles of the proteins in cancer and inflammation. Chemical synthesis and in vitro binding and activity assays of...
BC Innovations | Oct 20, 2016
Distillery Therapeutics


INDICATION: Melanoma Patient sample and mouse studies suggest cutaneous expression of the Treg-attracting chemokine CCL22 could help treat metastatic melanoma. In samples of patient skin metastases, levels of CCL22 were higher than in healthy volunteer...
BC Week In Review | Sep 26, 2016
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

The Max Delbrueck Center ( MDC ) granted Wilex’s Heidelberg Pharma GmbH subsidiary an option to license humanized antibodies against tumor necrosis factor (TNF) receptor superfamily member 17 ( BCMA ; TNFRSF17 ; CD269 ). Heidelberg designated HDP-101...
BC Innovations | May 28, 2015
Distillery Therapeutics

Therapeutics: Phosphodiesterase 3A, bGMP-inhibited (PDE3A)

Cardiovascular disease INDICATION: Hypertension Genetic and in vitro studies suggest inhibiting PDE3A on vascular smooth muscle cells could help treat inherited hypertension and brachydactyly type E (HTNB). Whole-genome sequencing of 48 HTNB patients from 6...
BC Week In Review | Mar 24, 2014
Clinical News

BNC105: Phase II data

Data from 136 evaluable patients with metastatic RCC who failed prior tyrosine kinase inhibitor (TKI) therapy in the Phase II portion of the open-label, dose-escalation, international Phase I/II DISRUPTOR-1 trial showed that IV BNC105 plus...
BC Innovations | Nov 21, 2013
Targets & Mechanisms

Getting to the root of periodontitis

Current periodontitis therapies do not target the underlying immune response that drives the disease. A team from the U.S. and Brazil is looking to change that and has shown that microparticles loaded with chemokine CC...
BC Innovations | Nov 21, 2013
Distillery Therapeutics

Indication: Dental disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Dental disease Periodontitis Chemokine CC motif ligand 22 (CCL22) Animal studies suggest CCL22-loaded microparticles could help treat periodontitis. In mouse models of...
BC Week In Review | May 2, 2011
Company News

Affitech, Cancer Research U.K. deal

Affitech received exclusive, worldwide rights from Cancer Research's Cancer Research Technology Ltd. commercial arm to a patent application and IP to develop antibodies against tumor protein CC chemokine receptor 4 (CCR4; CD194 ). Affitech said...
Items per page:
1 - 10 of 19